SOPHiA GENETICS (SOPH) Q4 2025 earnings review
Accelerating Top-Line Momentum Marred by Widening IFRS Net Losses
SOPHiA GENETICS delivered a strong close to 2025, posting 22% YoY revenue growth in Q4 and driving Net Dollar Retention up to 115%. The core growth engine is firing, fueled by a 50% surge in U.S. analysis volumes and the rapid adoption of its MSK-ACCESS liquid biopsy application. However, the path to profitability remains murky on a statutory basis. While management touts improving Adjusted Gross Margins (74.2% for FY25), actual IFRS Net Loss widened by 27% in Q4 and 26% for the full year, pressured by litigation costs and FX headwinds. FY26 guidance projects robust 20-22% revenue growth and narrowing adjusted EBITDA losses, but the company must prove it can translate scale into true bottom-line cash generation.
🐂 Bull Case
U.S. analysis volume surged 50% YoY in Q4. Two newly signed major U.S. integrated healthcare systems will add 60,000 analyses annually, significantly boosting forward revenue visibility.
Net Dollar Retention (NDR) jumped from 104% in FY24 to 115% in FY25, proving the platform's stickiness and the success of cross-selling higher-value applications like MSK-ACCESS.
🐻 Bear Case
Despite adjustments showing improvement, the actual IFRS net loss widened to $79.0M in FY25. With a cash drop to $70.3M and borrowings surging to $47.7M, the balance sheet is taking on more leverage to fund operations.
Guardant Health's patent infringement lawsuits generated $2.4M in legal expenses in H2 2025. Even with some initial court victories, ongoing appeals and parallel UK proceedings introduce operational distraction and financial risk.
⚖️ Verdict: ⚪
Neutral. The commercial execution is phenomenal—revenue is accelerating, ACVs are up 120%, and U.S. penetration is working. But a 27% wider Q4 net loss and rising debt balances highlight that hyper-growth is still coming at a heavy cost.
Key Themes
U.S. Market Penetration Accelerating
The United States has firmly become SOPHiA's primary growth engine. Q4 saw a massive 50% YoY increase in U.S. analysis volume, bringing FY25 U.S. volume growth to 27%. The signing of two major West Coast and Midwest integrated health systems, expected to ramp in H2 2026, guarantees significant future volume (60,000 patients annually). This shift toward larger enterprise contracts is driving economies of scale.
MSK-ACCESS and BioPharma Rebound
The company’s shift to higher-ASP applications is paying off. The MSK-ACCESS liquid biopsy application saw over 7,500 analyses in FY25 with over 70 customers signed. Furthermore, the previously lagging BioPharma segment has reversed its trend, buoyed by four distinct new partner contracts and a global commercial agreement with a top-5 oncology pharmaceutical company.
Guardant Health Litigation Costs
Legal battles are severely impacting operating expenses. SOPHiA incurred $2.4M in litigation expenses in H2 2025 defending against Guardant Health's patent infringement suits. While SOPHiA won an interim cost award in the Paris UPC, Guardant is appealing, and UK proceedings remain pending. This overhang threatens to drain cash and cap near-term margin expansion.
IFRS Net Loss Contradicts Profitability Narrative
Management's narrative heavily leans on an 'improving path to adjusted EBITDA breakeven.' However, actual IFRS Net Loss widened by 26% to $79.0M for FY25. This was driven by a $2.6M spike in interest expense, a $6.9M negative swing in FX, and a $5.6M increase in General & Administrative costs. Growth is accelerating, but the real cash cost of that growth is still rising.
Macro Shift to Decentralized Testing
The macro environment continues to heavily favor SOPHiA's decentralized model. As sequencer costs fall and data generation explodes, large health systems and BioPharma companies are actively moving away from centralized lab monopolies. SOPHiA’s platform acts as the critical bioinformatics infrastructure enabling this in-house testing shift globally.
Platform Efficiency and Gross Margins
Despite processing 40% more terabytes of data YoY, Adjusted Gross Margin expanded 140 basis points to 74.2% in FY25. The transition of the SOPHiA DDM platform from Java to Web and microservices has effectively decoupled compute costs from volume growth, showcasing pure software-like operating leverage at the gross margin line.
Other KPIs
Stable. Adjusted gross margin hit 74.2% in FY25, up from 72.8% in FY24. This validates management's claims that their cloud-native infrastructure optimizations are absorbing massive data volume increases without proportional cost hikes.
Accelerating. Up significantly from $13.2M at the end of 2024. The company drew down a $35M second tranche from its Perceptive Credit Agreement to fortify the balance sheet. While cash remains solid at $70.3M, the interest expense burden jumped 138% YoY to $4.6M.
Accelerating. The company is successfully executing its strategy to move upmarket, landing larger enterprise-level academic and central lab accounts rather than small individual clinics. This drives the robust Net Dollar Retention improvement.
Guidance
Accelerating. The midpoint of $93M implies 20.4% YoY growth, a meaningful acceleration from the 19% delivered in FY25. This reflects the layering of BioPharma revenues and the delayed onboarding of massive U.S. healthcare accounts.
Reversing. After expanding from a $40.2M loss in FY24 to a $41.5M loss in FY25, guidance indicates losses will finally narrow in FY26. Management targets crossing into positive Adjusted EBITDA by the second half of 2027.
Key Questions
Timeline for U.S. Health System Implementations
You highlighted two major integrated U.S. healthcare systems that will add 60,000 analyses annually, but noted they will ramp in H2 2026. What are the specific implementation bottlenecks preventing an earlier revenue contribution from these massive deals?
Guardant Litigation Costs in Guidance
With $2.4M spent on the Guardant Health litigation in H2 2025 alone, how much legal expense is baked into your FY26 Adjusted EBITDA guidance of $(29)-$(32) million? Is there a risk this could blow out your profitability timeline if appeals drag on?
Bridging IFRS Net Loss to Adjusted EBITDA
While Adjusted EBITDA is guided to improve significantly, IFRS net loss widened by 26% this year due to FX, social charges, and interest. Do you expect IFRS net loss to also peak and reverse in 2026, or will cash burn remain disconnected from adjusted metrics?
Capital Sufficiency
You ended the year with $70.3M in cash and $47.7M in debt. Given the $35.9M in operating cash burn in 2025, do you have sufficient liquidity to reach your H2 2027 positive Adjusted EBITDA target without needing to tap the equity markets again?